ALPN-101 (Acazicolcept) in Systemic Lupus Erythematosus
- Registration Number
- NCT04835441
- Lead Sponsor
- Alpine Immune Sciences, Inc.
- Brief Summary
This is Phase 2, multinational, randomized, blinded study to evaluate the safety, tolerability, efficacy, immunogenicity, pharmacokinetics and pharmacodynamics of ALPN-101 (acazicolcept) in adults with moderate to severe active systemic lupus erythematosus (SLE)
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 76
Not provided
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description ALPN-101 (acazicolcept) ALPN-101 - Placebo Placebo -
- Primary Outcome Measures
Name Time Method Adverse Events From study Day 1 until End of Study (28 weeks) Type, incidence, and severity of adverse events as assessed by CTCAE
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (46)
Investigational Site (107)
🇺🇸Anniston, Alabama, United States
Investigational Site (189)
🇺🇸Phoenix, Arizona, United States
Investigational Site (155)
🇺🇸Los Angeles, California, United States
Investigational Site (109)
🇺🇸San Diego, California, United States
Investigational Site (169)
🇺🇸Santa Barbara, California, United States
Investigational Site (106)
🇺🇸DeBary, Florida, United States
Investigational Site (120)
🇺🇸Hialeah, Florida, United States
Investigational Sites (134)
🇺🇸Miami, Florida, United States
Investigational Site (152)
🇺🇸Ormond Beach, Florida, United States
Investigational Site (133)
🇺🇸Plantation, Florida, United States
Scroll for more (36 remaining)Investigational Site (107)🇺🇸Anniston, Alabama, United States